Cargando…

Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone

BACKGROUND: Different effectiveness profiles among second-generation antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to affect long-term outcome. The aim of this study was to compare the clinical effectiveness of aripiprazole, ziprasidone, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez-Revuelta, Marcos, Pelayo-Terán, José María, Juncal-Ruiz, María, Ortiz-García de la Foz, Víctor, Vázquez-Bourgon, Javier, González-Pinto, Ana, Crespo-Facorro, Benedicto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276055/
https://www.ncbi.nlm.nih.gov/pubmed/30215723
http://dx.doi.org/10.1093/ijnp/pyy082
_version_ 1783377939051577344
author Gómez-Revuelta, Marcos
Pelayo-Terán, José María
Juncal-Ruiz, María
Ortiz-García de la Foz, Víctor
Vázquez-Bourgon, Javier
González-Pinto, Ana
Crespo-Facorro, Benedicto
author_facet Gómez-Revuelta, Marcos
Pelayo-Terán, José María
Juncal-Ruiz, María
Ortiz-García de la Foz, Víctor
Vázquez-Bourgon, Javier
González-Pinto, Ana
Crespo-Facorro, Benedicto
author_sort Gómez-Revuelta, Marcos
collection PubMed
description BACKGROUND: Different effectiveness profiles among second-generation antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to affect long-term outcome. The aim of this study was to compare the clinical effectiveness of aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up. METHOD: From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. Two hundred-two first-episode, drug-naïve patients were randomly assigned to aripiprazole (n=78), ziprasidone (n =62), or quetiapine (n=62) and followed-up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on the intention-to-treat principle was conducted in the analysis for clinical efficacy. RESULTS: The overall dropout rate at 3 years reached 19.3%. Treatment discontinuation rates were significantly different among treatment groups (aripiprazole=73.08%, ziprasidone=79.03%, and quetiapine=95.16%) (χ2=11.680; P=.001). Statistically significant differences in terms of nonefficacy, nonadherence, and side effects were observed among treatment groups along the 3-year follow-up determining significant differences in time to all-cause discontinuation (log-rank=32.260; P=.001). Significant differences between treatments were found in the categories of sleepiness/sedation (χ(2)=9.617; P=.008) and increased sleep duration (χ(2)=6.192; P=.004). No significant differences were found in the profile of extrapyramidal symptoms. Patients on aripiprazole were more likely to be prescribed benzodiazepines. CONCLUSIONS: First-episode psychosis patients on quetiapine were more likely to discontinue treatment due to nonefficacy. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis.
format Online
Article
Text
id pubmed-6276055
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62760552018-12-06 Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone Gómez-Revuelta, Marcos Pelayo-Terán, José María Juncal-Ruiz, María Ortiz-García de la Foz, Víctor Vázquez-Bourgon, Javier González-Pinto, Ana Crespo-Facorro, Benedicto Int J Neuropsychopharmacol Regular Research Articles BACKGROUND: Different effectiveness profiles among second-generation antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to affect long-term outcome. The aim of this study was to compare the clinical effectiveness of aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up. METHOD: From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. Two hundred-two first-episode, drug-naïve patients were randomly assigned to aripiprazole (n=78), ziprasidone (n =62), or quetiapine (n=62) and followed-up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on the intention-to-treat principle was conducted in the analysis for clinical efficacy. RESULTS: The overall dropout rate at 3 years reached 19.3%. Treatment discontinuation rates were significantly different among treatment groups (aripiprazole=73.08%, ziprasidone=79.03%, and quetiapine=95.16%) (χ2=11.680; P=.001). Statistically significant differences in terms of nonefficacy, nonadherence, and side effects were observed among treatment groups along the 3-year follow-up determining significant differences in time to all-cause discontinuation (log-rank=32.260; P=.001). Significant differences between treatments were found in the categories of sleepiness/sedation (χ(2)=9.617; P=.008) and increased sleep duration (χ(2)=6.192; P=.004). No significant differences were found in the profile of extrapyramidal symptoms. Patients on aripiprazole were more likely to be prescribed benzodiazepines. CONCLUSIONS: First-episode psychosis patients on quetiapine were more likely to discontinue treatment due to nonefficacy. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis. Oxford University Press 2018-09-12 /pmc/articles/PMC6276055/ /pubmed/30215723 http://dx.doi.org/10.1093/ijnp/pyy082 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of CINP. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Regular Research Articles
Gómez-Revuelta, Marcos
Pelayo-Terán, José María
Juncal-Ruiz, María
Ortiz-García de la Foz, Víctor
Vázquez-Bourgon, Javier
González-Pinto, Ana
Crespo-Facorro, Benedicto
Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone
title Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone
title_full Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone
title_fullStr Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone
title_full_unstemmed Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone
title_short Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone
title_sort long-term antipsychotic effectiveness in first episode of psychosis: a 3-year follow-up randomized clinical trial comparing aripiprazole, quetiapine, and ziprasidone
topic Regular Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276055/
https://www.ncbi.nlm.nih.gov/pubmed/30215723
http://dx.doi.org/10.1093/ijnp/pyy082
work_keys_str_mv AT gomezrevueltamarcos longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone
AT pelayoteranjosemaria longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone
AT juncalruizmaria longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone
AT ortizgarciadelafozvictor longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone
AT vazquezbourgonjavier longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone
AT gonzalezpintoana longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone
AT crespofacorrobenedicto longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone